Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

YKL-40, a chitinase-like glycoprotein associated with inflammation and tissue remodeling, is produced by joint tissues and recognized as a candidate auto-antigen in rheumatoid arthritis (RA). In the present study, we investigated YKL-40 as a potential biomarker of disease activity in patients with e...

Full description

Bibliographic Details
Main Authors: Tuija Väänänen, Katriina Vuolteenaho, Hannu Kautiainen, Riina Nieminen, Timo Möttönen, Pekka Hannonen, Markku Korpela, Markku J Kauppi, Kari Laiho, Oili Kaipiainen-Seppänen, Riitta Luosujärvi, Tea Uusitalo, Toini Uutela, Marjatta Leirisalo-Repo, Eeva Moilanen, NEO-RACo Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5571914?pdf=render

Internet

http://europepmc.org/articles/PMC5571914?pdf=render

Similar Items